糖尿病与COVID-19:大流行18个月的人群影响
本文综述了糖尿病与COVID-19相关发病和死亡的关系。约30-40%的COVID-19住院、重症或死亡患者伴有糖尿病;糖尿病患者重症和死亡风险比无糖尿病者高100-250%。总体死亡率较历史趋势高50%,超额死亡中约75-80%未归因于COVID-19。
要点
- 约30-40%的COVID-19住院、重症或死亡患者有糖尿病。
- 糖尿病患者重症和死亡风险比无糖尿病者高100-250%。
- 糖尿病患者总体死亡率较历史趋势高50%,超额死亡多未归因COVID-19。
核心结论
- 糖尿病是COVID-19重症发病的中心 contributory 因素,COVID-19对糖尿病人群有毁灭性影响。
- 糖尿病患者重症和死亡风险显著高于无糖尿病者,即使调整社会人口学和合并症因素后仍如此。
- 糖尿病患者总体死亡率较历史趋势高50%,净增加超过一般人群的两倍。
- 超额死亡中约75-80%未官方归因于COVID-19,提示漏归因或间接影响。
研究设计与样本
- 文献综述(literature synthesis),总结糖尿病与COVID-19相关发病和死亡的关系。
- 讨论严重不良结局的预测因素及整体大流行的影响。
- 评述流行病学研究的现状并确定下一阶段需求。
主要发现
- 约30-40%的COVID-19相关住院、需重症监护的严重发病和/或死亡患者有2型或1型糖尿病。
- 住院糖尿病患者中约21-43%需要重症监护,病死率约25%。
- 糖尿病患者重症和死亡风险比无糖尿病者高100-250%,即使调整社会人口学因素和合并症后。
- 糖尿病患者总体死亡率比历史趋势高50%,净增加超过一般人群的两倍。
- 超额死亡中约75-80%未官方归因于COVID-19。
关键数值与推荐
- 已识别的不良结局预测因素包括合并症(慢性肾病、冠心病、心力衰竭)、并发肥胖以及急性和慢性HbA1c控制不佳。
临床怎么用
- 关注糖尿病患者的合并症(慢性肾病、冠心病、心力衰竭)、肥胖和HbA1c控制以降低重症和死亡风险。
- 需开展更广泛的人群研究评估暴露、感染和住院风险。
- 需量化大流行对卫生服务、健康行为、疾病管理、护理、控制和并发症的间接影响。
- 需将流行病学研究扩展到高收入国家之外,以限制中低收入国家的负担。
局限性
- 暴露、感染和住院风险的人群数据目前很少。
- 大流行对卫生服务、健康行为、疾病管理等的间接影响尚未很好量化。
- 流行病学研究多限于少数高收入国家。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Eighteen months into the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) pandemic, epidemiologic studies indicate that diabetes is a central contributor to severe COVID-19 morbidity, and, conversely, COVID-19 has had a devastating effect on the population with diabetes. In this literature synthesis, we summarize the relationship of diabetes to COVID-19-related morbidity and mortality, discuss the predictors of severe adverse outcomes and implications of the overall pandemic, and critique the current status of and identify needs for epidemiologic studies for the next phase of the pandemic. Case series show that ∼30-40% of people with COVID-19-related hospitalization, severe morbidity requiring intensive care, and/or death have type 2 or type 1 diabetes. Among hospitalized individuals with diabetes, ∼21-43% required intensive care and case fatality is ∼25%. Risk of severe morbidity and mortality is 100-250% higher among people with diabetes than those without, even after adjustment for sociodemographic factors and comorbid conditions. Impact on the general population with diabetes has been similarly dire, as overall mortality rates were 50% higher than historical trends, a net increase more than twice that of the general population. Of the excess deaths, ∼75-80% are not officially attributed to COVID-19, which raises unanswered questions about missed attribution or collateral impact. Many predictors of poor outcomes have been identified, particularly comorbid conditions (chronic kidney disease, coronary heart disease, and heart failure), concurrent obesity, and acute and chronic poor HbA1c control, that point to the potential to reduce severe morbidity and mortality in its next stages. However, response to the continuing pandemic will benefit from population-wide studies with broader examination of the risks of exposure, infection, and hospitalization, for which few data currently exist. The indirect impact of the pandemic's effects on health services, health behaviors, disease management, care, control, and complications has not been well quantified; determining this impact will be essential to lessen the future impact. Expanding epidemiologic studies of the relationship of diabetes to COVID-19 beyond few high-income countries will also be essential to limit the burden in low- and middle-income countries where 80% of individuals with diabetes reside and where the COVID-19 pandemic has been so damaging.
引用
- Gregg EW, Sophiea MK, Weldegiorgis M, et al. Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic. Diabetes Care. 2021. PMID: 34244333. doi:10.2337/dci21-0001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。